CN102417894A - 一种提高诱导生成多能性干细胞效率的方法 - Google Patents
一种提高诱导生成多能性干细胞效率的方法 Download PDFInfo
- Publication number
- CN102417894A CN102417894A CN2011103237797A CN201110323779A CN102417894A CN 102417894 A CN102417894 A CN 102417894A CN 2011103237797 A CN2011103237797 A CN 2011103237797A CN 201110323779 A CN201110323779 A CN 201110323779A CN 102417894 A CN102417894 A CN 102417894A
- Authority
- CN
- China
- Prior art keywords
- stem cells
- oct4
- multipotent stem
- jhdm1b
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002894 multi-fate stem cell Anatomy 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000006698 induction Effects 0.000 title abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 94
- 210000000130 stem cell Anatomy 0.000 claims abstract description 73
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims abstract description 72
- 230000001939 inductive effect Effects 0.000 claims abstract description 72
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims abstract description 43
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims abstract description 36
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 20
- 239000011718 vitamin C Substances 0.000 claims abstract description 20
- 108091023040 Transcription factor Proteins 0.000 claims description 40
- 102000040945 Transcription factor Human genes 0.000 claims description 40
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 230000008859 change Effects 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 238000010010 raising Methods 0.000 claims description 19
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 14
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 14
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 241001430294 unidentified retrovirus Species 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 230000017858 demethylation Effects 0.000 claims description 6
- 238000010520 demethylation reaction Methods 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108091027963 non-coding RNA Proteins 0.000 claims description 3
- 102000042567 non-coding RNA Human genes 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 abstract description 8
- 230000005540 biological transmission Effects 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 2
- 229930003268 Vitamin C Natural products 0.000 abstract 2
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 231100000175 potential carcinogenicity Toxicity 0.000 abstract 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 210000001671 embryonic stem cell Anatomy 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 13
- 101150086694 SLC22A3 gene Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 12
- 210000001778 pluripotent stem cell Anatomy 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 230000008672 reprogramming Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 108091029523 CpG island Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000011987 methylation Effects 0.000 description 7
- 238000007069 methylation reaction Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- -1 Nanog Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 102000008157 Histone Demethylases Human genes 0.000 description 4
- 108010074870 Histone Demethylases Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 241000251477 Chimaera Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101150099612 Esrrb gene Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000228143 Penicillium Species 0.000 description 3
- 101710150336 Protein Rex Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 101150111214 lin-28 gene Proteins 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101100239628 Danio rerio myca gene Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000058057 JmjC domain-containing Human genes 0.000 description 2
- 108700001203 JmjC domain-containing Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101100058542 Danio rerio bmi1a gene Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100038000 F-box only protein 15 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 101000878635 Homo sapiens F-box only protein 15 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100405132 Mus musculus Nr5a2 gene Proteins 0.000 description 1
- 101100137157 Mus musculus Pou5f1 gene Proteins 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150013593 Nr5a1 gene Proteins 0.000 description 1
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 1
- 101710105538 Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000004028 Octamer Transcription Factors Human genes 0.000 description 1
- 108010082496 Octamer Transcription Factors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150041227 PMX gene Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 108010013721 SOX Transcription Factors Proteins 0.000 description 1
- 102000017100 SOX Transcription Factors Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 108050000630 Transcription factor SOX-2 Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (12)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103237797A CN102417894B (zh) | 2011-10-21 | 2011-10-21 | 一种提高诱导生成多能性干细胞效率的方法 |
EP12801798.5A EP2647700B1 (en) | 2011-10-21 | 2012-03-31 | Method for increasing efficiency of generating inducted pluripotent stem cell |
EP13167122.4A EP2778222B1 (en) | 2011-10-21 | 2012-03-31 | Method for increasing the efficiency of inducing pluripotent stem cells |
ES13167122.4T ES2628912T3 (es) | 2011-10-21 | 2012-03-31 | Método para aumentar la eficacia de inducción de células madre pluripotentes |
JP2013539131A JP5736052B2 (ja) | 2011-10-21 | 2012-03-31 | 多能性幹細胞の誘導生成効率を高める方法 |
ES12801798.5T ES2627799T3 (es) | 2011-10-21 | 2012-03-31 | Método para aumentar la eficiencia de la generación de célula pluripotente inducida |
US13/808,596 US9163217B2 (en) | 2011-10-21 | 2012-03-31 | Method for increasing the efficiency of inducing pluripotent stem cells |
PCT/CN2012/073375 WO2013056535A1 (zh) | 2011-10-21 | 2012-03-31 | 一种提高诱导生成多能性干细胞效率的方法 |
JP2013111944A JP5738347B2 (ja) | 2011-10-21 | 2013-05-28 | 多能性幹細胞の誘導生成効率を高める方法 |
US14/011,714 US9163218B2 (en) | 2011-10-21 | 2013-08-27 | Method for increasing the efficiency of inducing pluripotent stem cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103237797A CN102417894B (zh) | 2011-10-21 | 2011-10-21 | 一种提高诱导生成多能性干细胞效率的方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310072228.7A Division CN103173490B (zh) | 2011-10-21 | 2011-10-21 | 一种提高诱导生成多能性干细胞效率的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102417894A true CN102417894A (zh) | 2012-04-18 |
CN102417894B CN102417894B (zh) | 2013-06-05 |
Family
ID=45942538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103237797A Active CN102417894B (zh) | 2011-10-21 | 2011-10-21 | 一种提高诱导生成多能性干细胞效率的方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9163217B2 (zh) |
EP (2) | EP2778222B1 (zh) |
JP (2) | JP5736052B2 (zh) |
CN (1) | CN102417894B (zh) |
ES (2) | ES2627799T3 (zh) |
WO (1) | WO2013056535A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104212762A (zh) * | 2014-08-25 | 2014-12-17 | 中国人民解放军总医院 | 一种通过体外小分子诱导培养尿源性多潜能干细胞的方法 |
CN104611295A (zh) * | 2015-02-06 | 2015-05-13 | 华南农业大学 | 一种食蟹猴睾丸间质祖细胞永生系的建立方法 |
CN104630136A (zh) * | 2013-11-15 | 2015-05-20 | 中国科学院广州生物医药与健康研究院 | 一种制备诱导多能性干细胞的方法以及该方法中所使用的组合物及其应用 |
CN105018430A (zh) * | 2015-02-06 | 2015-11-04 | 华南农业大学 | 一种长白仔猪骨髓间充质干细胞永生系的建立方法 |
CN106544315A (zh) * | 2016-10-12 | 2017-03-29 | 广东艾时代生物科技有限责任公司 | 一种脂肪间充质干细胞诱导成多能干细胞的方法 |
CN107286232A (zh) * | 2017-05-23 | 2017-10-24 | 中国科学院广州生物医药与健康研究院 | Pou结构域改造蛋白对多能干细胞的高效诱导 |
CN108220230A (zh) * | 2018-02-01 | 2018-06-29 | 上海莱馥生命科学技术有限公司 | 一种人脂肪干细胞的分离与培养方法 |
CN108441517A (zh) * | 2018-03-28 | 2018-08-24 | 长春博邦企业管理咨询有限公司 | 一种人诱导多能干细胞的制备方法 |
CN109072200A (zh) * | 2015-12-23 | 2018-12-21 | 莫纳什大学 | 细胞重编程 |
CN110241087A (zh) * | 2012-05-13 | 2019-09-17 | 美国绿阳生物技术及医药公司 | 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞 |
CN112063656A (zh) * | 2020-08-28 | 2020-12-11 | 中国科学院广州生物医药与健康研究院 | Map2k3或Map2k6在提高诱导成体细胞生成多能性干细胞效率中的用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11203739B2 (en) * | 2014-04-07 | 2021-12-21 | Memorial Sloan-Kettering Cancer Center | Modulating cell proliferation and pluripotency |
US11136552B2 (en) | 2015-10-28 | 2021-10-05 | Keio University | Method for reducing differentiation resistance of pluripotent stem cells |
JP2018143239A (ja) | 2017-03-01 | 2018-09-20 | エリクサジェン,エルエルシー. | 多能性幹細胞を所望の細胞型へ効率的に分化する方法 |
CN110724706B (zh) * | 2018-07-17 | 2023-03-10 | 中国科学院上海营养与健康研究所 | Oct4泛素化修饰突变体在提高诱导体细胞重编程效率中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143421A2 (en) * | 2008-05-22 | 2009-11-26 | The Johns Hopkins University | Methods for promoting fusion and reprogramming of somatic cells |
CN101684455A (zh) * | 2009-07-22 | 2010-03-31 | 中国科学院广州生物医药与健康研究院 | 抗坏血酸在诱导多能干细胞制备和胚胎干细胞培养的应用 |
CN101744808A (zh) * | 2009-12-15 | 2010-06-23 | 中国科学院广州生物医药与健康研究院 | 抗坏血酸的新用途 |
WO2010124143A1 (en) * | 2009-04-23 | 2010-10-28 | Nevada Cancer Institute | Reprogramming of somatic cells with purified proteins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079417A2 (en) | 2001-03-28 | 2002-10-10 | President And Fellows Of Harvard College | Methods of delivery of exogenous proteins to the cytosol and uses thereof |
US20090275032A1 (en) * | 2005-08-01 | 2009-11-05 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator |
US8357666B2 (en) | 2005-08-01 | 2013-01-22 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through RNA interference |
AU2006308957B2 (en) * | 2005-10-28 | 2012-04-12 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a JmjC domain |
AU2009234424A1 (en) * | 2008-04-07 | 2009-10-15 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator |
WO2010108126A2 (en) * | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
GB0918862D0 (en) * | 2009-10-27 | 2009-12-09 | Glaxo Group Ltd | Method of treatment |
US8759098B2 (en) * | 2009-12-04 | 2014-06-24 | Boston Biomedical Research Institute, Inc. | Method for cloning pluripotent stem cells |
-
2011
- 2011-10-21 CN CN2011103237797A patent/CN102417894B/zh active Active
-
2012
- 2012-03-31 EP EP13167122.4A patent/EP2778222B1/en not_active Not-in-force
- 2012-03-31 ES ES12801798.5T patent/ES2627799T3/es active Active
- 2012-03-31 WO PCT/CN2012/073375 patent/WO2013056535A1/zh active Application Filing
- 2012-03-31 EP EP12801798.5A patent/EP2647700B1/en not_active Not-in-force
- 2012-03-31 US US13/808,596 patent/US9163217B2/en not_active Expired - Fee Related
- 2012-03-31 JP JP2013539131A patent/JP5736052B2/ja not_active Expired - Fee Related
- 2012-03-31 ES ES13167122.4T patent/ES2628912T3/es active Active
-
2013
- 2013-05-28 JP JP2013111944A patent/JP5738347B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143421A2 (en) * | 2008-05-22 | 2009-11-26 | The Johns Hopkins University | Methods for promoting fusion and reprogramming of somatic cells |
WO2010124143A1 (en) * | 2009-04-23 | 2010-10-28 | Nevada Cancer Institute | Reprogramming of somatic cells with purified proteins |
CN101684455A (zh) * | 2009-07-22 | 2010-03-31 | 中国科学院广州生物医药与健康研究院 | 抗坏血酸在诱导多能干细胞制备和胚胎干细胞培养的应用 |
CN101744808A (zh) * | 2009-12-15 | 2010-06-23 | 中国科学院广州生物医药与健康研究院 | 抗坏血酸的新用途 |
Non-Patent Citations (3)
Title |
---|
CHANG PYO HONG等: "Epigenetic regulation in cell reprogramming revealed by genome-wide analysis", 《EPIGENOMICS》 * |
KAZUTOSHI TAKAHASHI等: "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors", 《CELL》 * |
KAZUTOSHI TAKAHASHI等: "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors", 《CELL》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110241087A (zh) * | 2012-05-13 | 2019-09-17 | 美国绿阳生物技术及医药公司 | 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞 |
CN110241087B (zh) * | 2012-05-13 | 2023-02-03 | 美国绿阳生物技术及医药公司 | 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞 |
CN104630136A (zh) * | 2013-11-15 | 2015-05-20 | 中国科学院广州生物医药与健康研究院 | 一种制备诱导多能性干细胞的方法以及该方法中所使用的组合物及其应用 |
WO2015070756A1 (zh) * | 2013-11-15 | 2015-05-21 | 中国科学院广州生物医药与健康研究院 | 一种制备诱导多能性干细胞的方法以及该方法中所使用的组合物及其应用 |
CN104630136B (zh) * | 2013-11-15 | 2019-10-01 | 中国科学院广州生物医药与健康研究院 | 一种制备诱导多能性干细胞的方法以及该方法中所使用的组合物及其应用 |
CN104212762A (zh) * | 2014-08-25 | 2014-12-17 | 中国人民解放军总医院 | 一种通过体外小分子诱导培养尿源性多潜能干细胞的方法 |
CN105018430A (zh) * | 2015-02-06 | 2015-11-04 | 华南农业大学 | 一种长白仔猪骨髓间充质干细胞永生系的建立方法 |
CN105018430B (zh) * | 2015-02-06 | 2018-08-31 | 华南农业大学 | 一种长白仔猪骨髓间充质干细胞永生系的建立方法 |
CN104611295A (zh) * | 2015-02-06 | 2015-05-13 | 华南农业大学 | 一种食蟹猴睾丸间质祖细胞永生系的建立方法 |
CN109072200A (zh) * | 2015-12-23 | 2018-12-21 | 莫纳什大学 | 细胞重编程 |
CN106544315A (zh) * | 2016-10-12 | 2017-03-29 | 广东艾时代生物科技有限责任公司 | 一种脂肪间充质干细胞诱导成多能干细胞的方法 |
CN107286232A (zh) * | 2017-05-23 | 2017-10-24 | 中国科学院广州生物医药与健康研究院 | Pou结构域改造蛋白对多能干细胞的高效诱导 |
CN108220230A (zh) * | 2018-02-01 | 2018-06-29 | 上海莱馥生命科学技术有限公司 | 一种人脂肪干细胞的分离与培养方法 |
CN108220230B (zh) * | 2018-02-01 | 2022-01-18 | 上海莱馥医疗科技有限公司 | 一种人脂肪干细胞的分离与培养方法 |
CN108441517A (zh) * | 2018-03-28 | 2018-08-24 | 长春博邦企业管理咨询有限公司 | 一种人诱导多能干细胞的制备方法 |
CN112063656A (zh) * | 2020-08-28 | 2020-12-11 | 中国科学院广州生物医药与健康研究院 | Map2k3或Map2k6在提高诱导成体细胞生成多能性干细胞效率中的用途 |
Also Published As
Publication number | Publication date |
---|---|
EP2647700A4 (en) | 2014-09-17 |
WO2013056535A9 (zh) | 2013-07-04 |
JP2014502153A (ja) | 2014-01-30 |
US9163217B2 (en) | 2015-10-20 |
EP2647700B1 (en) | 2017-03-15 |
JP2013230150A (ja) | 2013-11-14 |
ES2627799T3 (es) | 2017-07-31 |
ES2628912T3 (es) | 2017-08-04 |
EP2778222B1 (en) | 2017-03-22 |
JP5738347B2 (ja) | 2015-06-24 |
WO2013056535A1 (zh) | 2013-04-25 |
CN102417894B (zh) | 2013-06-05 |
US20130302893A1 (en) | 2013-11-14 |
EP2647700A1 (en) | 2013-10-09 |
JP5736052B2 (ja) | 2015-06-17 |
EP2778222A1 (en) | 2014-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102417894B (zh) | 一种提高诱导生成多能性干细胞效率的方法 | |
CN103003416B (zh) | 从小体积的外周血产生诱导性多潜能干细胞 | |
CN101356270B (zh) | 核重新编程因子 | |
JP2012509072A (ja) | 分化万能性状態への細胞の再プログラミング | |
CN102712903A (zh) | 从脐带血产生诱导的多能干细胞 | |
WO2022253022A1 (zh) | 一种基于单细胞测序数据分析的iPSC残留检测方法 | |
KR20130101135A (ko) | 유도 다능성 줄기세포 제조방법 및 유도 다능성 줄기세포 제조용 배지 | |
CN105051188A (zh) | 新颖方法 | |
CN112204149A (zh) | 重编程载体 | |
CN103173490B (zh) | 一种提高诱导生成多能性干细胞效率的方法 | |
CN114645023B (zh) | 将外周血单个核细胞重编程为诱导多能干细胞的系统和方法 | |
US9163218B2 (en) | Method for increasing the efficiency of inducing pluripotent stem cells | |
CN101684455B (zh) | 抗坏血酸在诱导多能干细胞制备和胚胎干细胞培养的应用 | |
Sharma et al. | Human Induced Pluripotent Stem Cell Production and Expansion from Blood using a Non‐Integrating Viral Reprogramming Vector | |
US9944901B2 (en) | Fusion protein for inducing pluripotent stem cells and application method thereof | |
CN102851314A (zh) | 诱导性多能干细胞的制备方法和用于制备诱导性多能干细胞的培养基 | |
Liu et al. | Synthetic mRNA reprogramming of human fibroblast cells | |
CN108384759A (zh) | 诱导皮肤成纤维细胞重编程的方法及其应用 | |
CN113046311B (zh) | 一种诱导多能干细胞定向分化为淋巴组织诱导细胞的方法 | |
CN112063656A (zh) | Map2k3或Map2k6在提高诱导成体细胞生成多能性干细胞效率中的用途 | |
CN109825468B (zh) | 一种高效诱导鱼类多能性干细胞的方法以及用于该方法的诱导培养基 | |
CN111471646B (zh) | 利用非抗生素筛选的游离型质粒载体制备iPSC的方法 | |
CN101671650B (zh) | 一种可高效诱导产生诱导多能干细胞(iPS)的诱导重编程方法 | |
CN116655774A (zh) | 过表达tlx的人诱导多能干细胞及其应用 | |
CN115074388A (zh) | 母源因子诱导的2c样全能干细胞及其转化应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181107 Address after: 230088 the 16 level of F5 two, two innovation industrial park, No. 2800, innovation Avenue, Hi-tech Zone, Hefei, Anhui. Patentee after: HEFEI ZHONGKE STEM CELL REGENERATION MEDICINE Co.,Ltd. Address before: 510663 open source Avenue 190, Science City, Guangzhou, Guangdong Patentee before: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220908 Address after: 510530 open source Avenue 190, Science City, Guangzhou, Guangdong Patentee after: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES Address before: 230088 the 16 level of F5 two, two innovation industrial park, No. 2800, innovation Avenue, Hi-tech Zone, Hefei, Anhui. Patentee before: HEFEI ZHONGKE STEM CELL REGENERATION MEDICINE Co.,Ltd. |
|
TR01 | Transfer of patent right |